Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China
1 other identifier
observational
200,000
1 country
1
Brief Summary
This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI. This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and team building will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 15, 2018
CompletedFirst Submitted
Initial submission to the registry
September 9, 2019
CompletedFirst Posted
Study publicly available on registry
September 13, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2035
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2035
October 9, 2019
September 1, 2019
17.5 years
September 9, 2019
October 8, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (31)
Aspirin at arrival
Proportion of aspirin use within 24 hours of admission among eligible patients
24 hours after admission
Clopidogrel (or ticagrelor) at arrival
Proportion of Clopidogrel (or ticagrelor) use within 24 hours of admission among eligible patients
24 hours after admission
β-blockers at arrival
Proportion of β-blockers use within 24 hours of admission among eligible patients
24 hours after admission
ECG at arrival
Proportion of ECG test within 10 minutes of admission among eligible patients
24 hours after admission
Reperfusion therapy rate
Reperfusion therapy rate is defined as utilization rate of thrombolytic therapy or primary PCI treatment among patients indicated with the reperfusion therapy.
24 hours after admission
Time delay from failure of fibrinolysis to angiography(The time from start of fibrinolysis to evaluation of its efficacy is 60-90min)
The proportion of failure of fibrinolysis to balloon within 90 minutes among all patients receiving PCI.
10 days on average (during hospitalization)
Time delay from start of fibrinolysis to angiography(if fibrinolysis is successful)
The proportion of from fibrinolysis to balloon (if fibrinolysis is successful) within 2-24hours among all patients receiving PCI.
10 days on average (during hospitalization)
Timeliness of thrombolytic therapy
The proportion of door to needle time (D2N) within 30 minutes among all patients receiving fibrinolytic therapy.
24 hours after admission
Timeliness of primary PCI
The proportion of door to balloon (D2B) within 90 minutes among all patients receiving primary PCI.
24 hours after admission
Door-in-Door-Out Time
Percentage of patients whose median time from the emergency department arrival at STEMI referral facility to emergency department discharge from STEMI referral facility is equal or less than 30 min. discharge from STEMI referral facility is 30 min.
24 hours after admission
Time to Primary PCI Among Transferred Patients
Percentage of patients whose median time from first medical contact (at or before emergency department arrival to the STEMI referral facility \[e.g., non-PCI-capable facility\]) to primary PCI at the STEMI receiving facility (PCI-capable facility) is equal or less than 120 min
24 hours after admission
Evaluation of LDL-C
Percentage of patients with documentation in the hospital record that LDL-C is evaluated during hospitalization
10 days on average (during hospitalization)
Evaluation of left ventricular ejection fraction
Percentage of patients with documentation in the hospital record that left ventricular ejection fraction is evaluated during hospitalization
10 days on average (during hospitalization)
Aspirin use during hospitalization
Proportion of Aspirin use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Clopidogrel (or ticagrelor) use during hospitalization
Proportion of Clopidogrel (or ticagrelor) use during hospitalization among eligible patients.
10 days on average (during hospitalization)
β-blockers use during hospitalization
Proportion of β-blockers use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use during hospitalization
Proportion of Angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Statins use during hospitalization
Proportion of statins use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Aspirin use at discharge
Proportion of aspirin use at discharge among eligible patients.
10 days on average (during hospitalization)
Clopidogrel (or ticagrelor) use at discharge
Proportion of Clopidogrel (or ticagrelor) use at discharge among eligible patients.
10 days on average (during hospitalization)
β-blockers use at discharge
Proportion of β-blockers use at discharge among eligible patients.
10 days on average (during hospitalization)
angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use at discharge
Proportion of angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use at discharge among eligible patients.
10 days on average (during hospitalization)
Statins use at discharge
Proportion of statins use at discharge among eligible patients.
10 days on average (during hospitalization)
Aldosterone Antagonist at Discharge
Proportion of Aldosterone Antagonist use at discharge among eligible patients.
10 days on average (during hospitalization)
Smoking cessation advice/ counseling at Discharge
Proportion of patients received smoking cessation advice/ counseling
10 days on average (during hospitalization)
all-cause mortality during hospitalization
Proportion of patients who were all-cause death during hospitalization
10 days on average (during hospitalization)
Cardiac mortality during hospitalization
Proportion of patients who were cardiac death during hospitalization
10 days on average (during hospitalization)
30-day all-cause mortality
Proportion of patients who were all-cause death from admission to 30days
From admission to 30days
30-day cardiac mortality
Proportion of patients who were cardiac death from admission to 30days
From admission to 30days
30-day readmission rates
Proportion of patients readmission from hospital discharge to 30days
From hospital discharge to 30 days
Cost during hospitalization
Cost during hospitalization
10 days on average (during hospitalization)
Study Arms (1)
All hospitals
All hospitals will take the treatment quality improvement strategies and tools into implementation. Intervention: Behavioral: Quality improvement strategies and tools
Interventions
Quality improvement strategies and tools
Eligibility Criteria
Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset
You may qualify if:
- Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hongjian Wang
Beijing, Beijing Municipality, 100037, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zhe Zheng
Chinese Academy of Medical Sciences, Fuwai Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 9, 2019
First Posted
September 13, 2019
Study Start
July 15, 2018
Primary Completion (Estimated)
December 31, 2035
Study Completion (Estimated)
December 31, 2035
Last Updated
October 9, 2019
Record last verified: 2019-09